Perspectives

1:43
The 1st iwCAR-T Meeting: facilitating shared knowledge on CAR T-cell therapy
David Maloney
2:40
Huge potential for CAR-T therapy in myeloma
Andrew Yee
1:58
With new treatment options in myeloma, is auto-SCT still necessary?
Inger Nijhof
1:03
The importance of patient empowerment
Karthik Ramasamy
3:23
A bright future for multiple myeloma
Kenneth Anderson
2:58
Patient perspectives in myeloma care: importance and incorporation
Karthik Ramasamy
2:37
CAR-T in myeloma: what is the potential?
Philip McCarthy
2:25
Increase in cancer patient transfers to the ICU: what does it come down to?
Michael von Bergwelt
1:33
Prevention of ICU over-crowding following CAR-T
Michael Darmon
1:32
Importance of the right treatment in CAR-T
Sigurdur Sigurdsson
1:48
Is the lack of ICU space an issue for CAR-T therapy?
Victoria Metaxa
1:14
Preparing the critical care workforce for CAR-T
Michael von Bergwelt
1:10
ICU admission in CAR-T treated patients
Élie Azoulay
2:47
CAR-T in the UK: updates from King’s College Hospital
Robin Sanderson
1:35
CAR-T therapy: ethical challenges
Victoria Metaxa
1:15
How could CAR-T affect transplantation in R/R lymphomas?
Robin Sanderson
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals